Dr. Aaron Field, an associate professor of neuro-radiology at the University of Wisconsin, said a “key factor” in the decision (to fund trials) was a meta-analysis of the research published so far... “Even when you took a very conservative approach to that meta-analysis, it still came out looking like there was an association there between CCSVI and MS..."


Scientists explain about-face on MS trials - thestar.com
www.thestar.com
The scientists who advised the federal government to go ahead with clinical trials for a controversial new treatment for multiple sclerosis say it was new evidence, not public pressure, that changed their minds.